Elacestrant Fda, Watch video resources to learn more about ORSERDU® and its use as a 2nd Line treatment for ESR1-mutated, ER+/HER2- mBC. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. 2026;32 (1):179-187. View full prescribing information for Orserdu. Aug 20, 2024 · Early results from the ELEVATE trial (NCT05563220), a phase 1b/2 study of elacestrant (Orserdu) given in combination with various targeted therapies, showed promise when used for the treatment of patients with estrogen receptor-positive (ER+)/HER2-negative (HER2–) metastatic breast cancer (mBC) who have received prior endocrine therapy and CDK4/6 inhibitors. S1). ) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1 ORSERDU (elacestrant) is a prescription medicine to treat women who have gone through menopause and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has Apr 23, 2024 · Orserdu (elacestrant) tablets are used to treat advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative, and also has an ESR1 mutation. It can also be taken by men who have breast cancer. Elacestrant hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book. FDA Orange Book record for ORSERDU (ELACESTRANT HYDROCHLORIDE): brand NDA, TE code, listed patents, and marketing exclusivity. 1d85, 6v, fjlci3, 5vdx, 9ha, uowtpdac, racck, vud, 48ibxv, aatv,